Recurrent Melanoma Recruiting Phase 1 Trials for DB06306 (Onalespib)

IndicationStatusPhase
DBCOND0028662 (Recurrent Melanoma)Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02097225Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryTreatment